Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürstenwalde – page 75

1 727 clinical trials in Fürstenwalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürstenwalde at a glance
1 727
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 727 trials in Fürstenwalde

Open in trial search

Dermatitis atopic

Not recruiting

Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride
  • Sponsor:Aribio Co. Ltd.

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Psoriasis

Not recruiting

Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-81241459
  • Sponsor:Janssen Cilag International

Colitis ulcerative+1

Not recruiting

Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Study on the Effectiveness and Safety of AVP-786 (Quinidine Sulfate and Deudextromethorphan Hydrobromide) for Treating Agitation in Alzheimer's Dementia Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Quinidine Sulfate
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Chronic kidney disease+1

Not recruiting

Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Study of Olezarsen (ISIS 678354) in Patients with Severe Hypertriglyceridemia: Testing Effects on Triglyceride Levels

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürstenwalde

What the registry says about research in the country

01 Respiratory Tract Diseases

Clinical research in Fürstenwalde Spree is focused on respiratory tract diseases, with all active studies centered on asthma and its more severe forms. These trials are looking at new treatment options, safety, and signs of better disease control for people with difficult-to-manage asthma.

  • Asthma and uncontrolled asthma
  • Severe eosinophilic asthma and eosinophilic phenotype
  • Moderate to severe controlled asthma under current guideline-based care
  • Testing new therapies and comparing them with existing treatments

The research includes studies of inhaled and biologic approaches, with an emphasis on improving symptom control, evaluating long-term safety, and measuring airway inflammation markers.

02 Asthma Treatment Safety and Tolerability

One part of the local trial landscape examines how well new asthma treatments are tolerated, especially in people already living with persistent disease. These studies help determine whether emerging options can offer benefits while remaining safe for everyday use.

  • Asthma treatment safety
  • Comparing different inhaled therapy formulations
  • Assessing long-term safety in ongoing care

This work supports clearer decisions about whether new therapies can be used comfortably and reliably in routine respiratory medicine.

03 Severe Eosinophilic Asthma

Several studies are dedicated to severe eosinophilic asthma, a more advanced form of asthma linked to ongoing inflammation. The goal is to see whether newer biologic treatments can improve control for patients who have already responded to specialized care.

  • Severe eosinophilic asthma
  • Evaluating biologic treatments for better disease control
  • Studying patients who benefited from prior anti-IL-5 or anti-IL-5R therapy

These trials aim to refine treatment choices for people with persistent eosinophilic airway inflammation and ongoing symptoms.

04 Biologic Therapies for Asthma

The research portfolio also includes studies of targeted biologic therapies for asthma, especially for patients with frequent symptoms or severe inflammatory disease. These trials are designed to test whether newer medicines can offer stronger and longer-lasting benefit than current options.

  • Biologic treatment strategies
  • Severe asthma management
  • Comparing new targeted therapies with established care

This area highlights a broader move toward more precise respiratory research that matches therapy to the underlying disease pattern.

05 Inflammation Markers and Asthma Control

Another important focus is the study of markers that reflect airway inflammation in asthma. By observing changes such as FeNO, researchers can better understand how well a treatment is affecting the underlying disease process.

  • Fraction of exhaled nitric oxide (FeNO)
  • Uncontrolled asthma
  • Evaluating whether new therapy can reduce airway inflammation

This kind of research helps improve both diagnosis and treatment monitoring in respiratory tract disease care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.